Posted by Michael Wonder on 23 Mar 2020
Intra-Cellular prices schizophrenia drug at $1,320 per month
23 March 2020 - Intra-Cellular Therapies said on Monday its lead drug to treat schizophrenia was now available at U.S. pharmacies for a list price of $1,320 a month.
The U.S. FDA in December approved the drug, Caplyta, as a once-daily dose of 42 mg, which had shown to regulate three neurotransmitter systems linked to severe mental illnesses.
Existing anti-psychotic drugs in the U.S. market include Rexulti from Danish drugmaker H. Lundbeck and Japan's Otsuka, Vraylar from Allergan, and Johnson & Johnson's Invega.
